Cargando…

Proteomic Biomarkers for Acute Interstitial Lung Disease in Gefitinib-Treated Japanese Lung Cancer Patients

Interstitial lung disease (ILD) events have been reported in Japanese non-small-cell lung cancer (NSCLC) patients receiving EGFR tyrosine kinase inhibitors. We investigated proteomic biomarkers for mechanistic insights and improved prediction of ILD. Blood plasma was collected from 43 gefitinib-trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nyberg, Fredrik, Ogiwara, Atsushi, Harbron, Chris G., Kawakami, Takao, Nagasaka, Keiko, Takami, Sachiko, Wada, Kazuya, Tu, Hsiao-Kun, Otsuji, Makiko, Kyono, Yutaka, Dobashi, Tae, Komatsu, Yasuhiko, Kihara, Makoto, Akimoto, Shingo, Peers, Ian S., South, Marie C., Higenbottam, Tim, Fukuoka, Masahiro, Nakata, Koichiro, Ohe, Yuichiro, Kudoh, Shoji, Clausen, Ib Groth, Nishimura, Toshihide, Marko-Varga, György, Kato, Harubumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140475/ https://www.ncbi.nlm.nih.gov/pubmed/21799770 http://dx.doi.org/10.1371/journal.pone.0022062

Ejemplares similares

Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer
por: Kawata, Toshio, et al.
Publicado: (2019)

A proteomic profile of synoviocyte lesions microdissected from formalin-fixed paraffin-embedded synovial tissues of rheumatoid arthritis
por: Hayashi, Junji, et al.
Publicado: (2015)

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations
por: Nishimura, Toshihide, et al.
Publicado: (2020)

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
por: Tamura, K, et al.
Publicado: (2008)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
por: Noro, Rintaro, et al.
Publicado: (2006)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
por: Beom, Seung-Hoon, et al.
Publicado: (2016)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

The direct and indirect action of inhaled agents on the lung and its circulation: lessons for clinical science.
por: Higenbottam, T, et al.
Publicado: (2001)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

Understanding the mechanisms of drug-associated interstitial lung disease
por: Higenbottam, T, et al.
Publicado: (2004)

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer
por: Suzumura, Tomohiro, et al.
Publicado: (2012)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma
por: WANG, ZHUN, et al.
Publicado: (2015)

Gefitinib-induced pyogenic granuloma in a patient with lung cancer
por: Sahoo, Satyajeet, et al.
Publicado: (2020)

Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma
por: Yang, Hong, et al.
Publicado: (2021)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)

Clinical Usefulness of CYFRA Assay in Diagnosing Lung Cancer: Measurement of Serum Cytokeratin Fragment
por: Sugama, Yasuo, et al.
Publicado: (1994)

The Effectiveness of Gefitinib on Spinal Metastases of Lung Cancer - Report of Two Cases -
por: Zukawa, Mineyuki, et al.
Publicado: (2008)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
por: Sudo, Makoto, et al.
Publicado: (2013)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2013)

The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India
por: Mehta, Asmita Anilkumar, et al.
Publicado: (2013)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
por: Shimomura, Iwao, et al.
Publicado: (2013)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
por: Carotenuto, Pietro, et al.
Publicado: (2011)

The combination astemizole–gefitinib as a potential therapy for human lung cancer
por: Chávez-López, María de Guadalupe, et al.
Publicado: (2017)

Delivery of gefitinib with an immunostimulatory nanocarrier improves therapeutic efficacy in lung cancer
por: Diao, Dingwei, et al.
Publicado: (2021)

In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer
por: Ni, Xiao Ling, et al.
Publicado: (2017)

Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases
por: Ryu, Yon Ju, et al.
Publicado: (2014)

Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care
por: Nishimura, Toshihide, et al.
Publicado: (2012)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

An adaptive trial design for updating the threshold of a continuous biomarker
por: Spencer, Amy, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0h5p2nt2lhg4rgftmh7e260d0k